Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18775468 | PHENYL ALCOHOLS FROM GAS FERMENTATION | July 2024 | December 2025 | Abandon | 17 | 3 | 0 | No | No |
| 18747818 | Peptides for Characterization of Botulinum Neurotoxins | June 2024 | March 2025 | Allow | 9 | 1 | 0 | No | No |
| 18741089 | DESTABILISING DOMAINS FOR CONDITIONALLY STABILISING A PROTEIN | June 2024 | September 2025 | Allow | 15 | 1 | 0 | Yes | No |
| 18672557 | COMPOSITIONS AND METHODS COMPRISING VARIANT MICROBIAL PROTEASES | May 2024 | July 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18604927 | METHODS AND COMPOSITIONS FOR GENOME EDITING | March 2024 | December 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18603491 | ENGINEERED ELECTRODE FOR ELECTROBIOCATALYSIS AND PROCESS TO CONSTRUCT THE SAME | March 2024 | July 2025 | Allow | 17 | 1 | 0 | No | No |
| 18598993 | METHODS FOR RAPID SEPARATION AND PURIFICATION OF DNA TOPOLOGICAL FORMS | March 2024 | March 2025 | Allow | 12 | 1 | 0 | No | No |
| 18589147 | METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS | February 2024 | August 2025 | Allow | 18 | 2 | 0 | No | No |
| 18432802 | VARIANT LOVD POLYPEPTIDES AND THEIR USES | February 2024 | March 2025 | Allow | 14 | 1 | 1 | No | No |
| 18419368 | HARVEST OPERATIONS FOR RECOMBINANT PROTEINS | January 2024 | March 2025 | Abandon | 13 | 0 | 1 | No | No |
| 18404227 | TOBACCO-DERIVED PROTEIN COMPOSITIONS | January 2024 | January 2026 | Allow | 25 | 3 | 1 | Yes | No |
| 18404392 | DESIGN OF PROTEIN GLYCOSYLATION SITES BY RAPID EXPRESSION AND CHARACTERIZATION OF N-GLYCOSYLTRANSFERASES | January 2024 | February 2025 | Allow | 13 | 1 | 0 | No | No |
| 18394404 | METHODS FOR PURIFICATION OF ARYLSULFATASE A | December 2023 | January 2025 | Allow | 13 | 1 | 0 | No | No |
| 18392928 | COMPOSITIONS AND METHODS FOR CONTROLLED MRNA TRANSLATION AND STABILITY | December 2023 | June 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18520960 | PICHIA PASTORIS STRAINS FOR PRODUCING PREDOMINANTLY HOMOGENEOUS GLYCAN STRUCTURE | November 2023 | March 2025 | Allow | 15 | 1 | 0 | Yes | No |
| 18515733 | CYSTEINE POLYSULFIDATION AND MITOCHONDRIAL BIOENERGETICS REGULATED BY CYSTEINYL-tRNA SYNTHETASE | November 2023 | December 2024 | Abandon | 13 | 1 | 0 | No | No |
| 18514046 | SAFE AND EFFECTIVE BETA-LACTAMASE DOSING FOR MICROBIOME PROTECTION | November 2023 | January 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18511046 | METHOD FOR PRODUCING BACTERIALLY SYNTHESIZED CELLULOSE NON-WOVEN | November 2023 | October 2025 | Allow | 23 | 1 | 0 | No | No |
| 18558849 | Optimization of a Thermophilic PHB Depolymerase for Industrial Applications | November 2023 | June 2025 | Allow | 20 | 2 | 1 | Yes | No |
| 18496409 | EXTENDED METABOLISM METHODS FOR INCREASING AND EXTRACTING METABOLITES FROM ALGAE AND MICROORGANISMS | October 2023 | May 2024 | Allow | 7 | 2 | 1 | Yes | No |
| 18286984 | PROMOTERS FOR VIRAL-BASED GENE THERAPY | October 2023 | March 2026 | Allow | 29 | 0 | 0 | Yes | No |
| 18376684 | PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT | October 2023 | February 2026 | Abandon | 28 | 3 | 1 | No | No |
| 18463979 | CODON OPTIMIZED GLA GENES AND USES THEREOF | September 2023 | September 2025 | Abandon | 24 | 3 | 0 | Yes | No |
| 18448864 | COMPOSITIONS AND METHODS FOR EXTRACTION OF MESENCHYMAL STEM CELLS | August 2023 | February 2026 | Allow | 30 | 3 | 0 | No | No |
| 18344690 | ENGINEERED BIOCATALYSTS AND METHODS FOR SYNTHESIZING CHIRAL AMINES | June 2023 | December 2024 | Allow | 18 | 1 | 0 | No | No |
| 18336636 | LUCIFERASE ENZYMES FOR USE WITH THERMOSTABLE LUCIFERINS IN BIOLUMINESCENT ASSAYS | June 2023 | October 2025 | Allow | 28 | 3 | 0 | Yes | No |
| 18329541 | REGULATION OF TRANSCRIPTION THROUGH CTCF LOOP ANCHORS | June 2023 | October 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18320575 | COMPOUNDS FOR TREATMENT OF OSTEOARTHRITIS | May 2023 | December 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18311555 | METHODS AND SYSTEMS FOR CELL-FREE BIODISCOVERY OF NATURAL PRODUCTS | May 2023 | February 2026 | Abandon | 34 | 2 | 0 | No | Yes |
| 18311000 | METHODS AND COMPOSITIONS FOR GENOME EDITING IN NON-DIVIDING CELLS | May 2023 | November 2023 | Allow | 7 | 0 | 0 | No | No |
| 18137604 | Cells for Characterization of Botulinum Neurotoxins | April 2023 | March 2024 | Allow | 11 | 1 | 0 | No | No |
| 18302387 | CLASS II, TYPE V CRISPR SYSTEMS | April 2023 | June 2024 | Allow | 14 | 0 | 0 | Yes | No |
| 18134291 | METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS | April 2023 | February 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18296687 | HUMAN KYNURENINASE ENZYMES AND USES THEREOF | April 2023 | July 2024 | Allow | 15 | 1 | 1 | No | No |
| 18179876 | Novel In Vitro and In Vivo Enrichment Strategy Targeting Lymphocytes Derived from Vector Transduced HSCS for Therapy of Disorders | March 2023 | March 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18179311 | METHYLATION-MEDIATED ADAPTER REMOVAL ON NUCLEIC ACID SEQUENCES | March 2023 | January 2026 | Allow | 35 | 1 | 0 | Yes | No |
| 18174569 | ADENOSINE NUCLEOBASE EDITORS AND USES THEREOF | February 2023 | January 2024 | Allow | 11 | 0 | 0 | Yes | No |
| 18165809 | METHODS AND COMPOSITIONS COMPRISING THERAPEUTIC GAMMA PEPTIDE NUCLEIC ACID-BASED MOLECULES | February 2023 | September 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18165023 | ALPHA-AMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | February 2023 | November 2024 | Allow | 21 | 2 | 0 | Yes | No |
| 18007178 | Cells Having Gene Duplications and Uses Thereof | January 2023 | February 2026 | Allow | 37 | 1 | 0 | Yes | No |
| 18098615 | METHODS FOR RAPID SEPARATION AND PURIFICATION OF DNA TOPOLOGICAL FORMS | January 2023 | December 2023 | Allow | 11 | 2 | 0 | Yes | No |
| 18153851 | Promoter of Hspa5 Gene | January 2023 | May 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18010762 | JELLYFISH COLLAGEN USE | December 2022 | October 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 18008758 | ASSESSING AND TREATING BIOLOGICAL AGING | December 2022 | January 2026 | Abandon | 38 | 1 | 0 | No | No |
| 18074660 | Conjugate Vaccines Containing Hydrazine-PEG-Hydrazine Linkers | December 2022 | January 2026 | Abandon | 38 | 0 | 1 | No | No |
| 18056853 | 2-O-Sulfation Enzyme Mutant and 3-O-Sulfation Enzyme Mutant, and Method for Using Same | November 2022 | July 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 18055274 | INCORPORATION OF UNNATURAL AMINO ACIDS INTO PROTEINS USING BASE EDITING | November 2022 | April 2024 | Allow | 18 | 1 | 0 | No | No |
| 17982673 | PLANT-DERIVED PROTEIN PURIFICATION | November 2022 | January 2025 | Abandon | 26 | 3 | 0 | No | No |
| 18045650 | CODON OPTIMIZED GLA GENES AND USES THEREOF | October 2022 | September 2023 | Allow | 11 | 2 | 0 | No | No |
| 17942543 | TREATMENT FOR UPGRADING HEAVY CRUDE OIL | September 2022 | March 2026 | Abandon | 42 | 1 | 0 | No | No |
| 17817223 | GENOME EDITING USING CRISPR IN CORYNEBACTERIUM | August 2022 | September 2024 | Abandon | 26 | 2 | 0 | No | No |
| 17875551 | TREATING ACUTE LIVER DISEASE WITH TLR-MIK INIHIBITORS | July 2022 | December 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17815128 | COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES | July 2022 | March 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 17814679 | Detergent Compositions and Uses of the Same | July 2022 | March 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17867602 | METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS | July 2022 | January 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17864255 | HARVEST OPERATIONS FOR RECOMBINANT PROTEINS | July 2022 | April 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17812359 | TREATING & PREVENTING E COLI INFECTIONS | July 2022 | December 2023 | Allow | 17 | 2 | 1 | Yes | No |
| 17791846 | TARGETED AND LOCALIZED IN VIVO DELIVERY OF OLIGONUCLEOTIDES | July 2022 | November 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17810396 | METHODS FOR PURIFICATION OF ARYLSULFATASE A | July 2022 | December 2023 | Allow | 17 | 1 | 0 | No | No |
| 17790484 | METHOD FOR TREATING USHER SYNDROME AND COMPOSITION THEREOF | June 2022 | October 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17790487 | LEAPER TECHNOLOGY BASED METHOD FOR TREATING MPS IH AND COMPOSITION | June 2022 | November 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17787343 | USE OF BIOMAGNETISM FOR BIOGAS PRODUCTION | June 2022 | November 2025 | Allow | 40 | 1 | 0 | No | No |
| 17807544 | PLANT LECTINS AS CARRIERS OF ASSOCIATED DRUG SUBSTANCES INTO ANIMAL AND HUMAN CELLS | June 2022 | January 2025 | Allow | 31 | 2 | 1 | Yes | No |
| 17785864 | GENETICALLY MODIFIED MICRORGANISMS THAT CARRY OUT THE HETEROLOGOUS PRODUCTION OF MODIFIED VERSIONS OF THE SURFACTANT PROTEIN LV-RANASPUMIN-1(LV-RSN-1), THE MODIFIED VERSIONS OF SAID SURFACTANT PROTEIN, THE SYNTHETIC GENES ENCODING SAID SURFACTANT PROTEIN, THE EXPRESSION CASSETTES CONTAINING SAID SYNTHETIC GENES, AND THE EXPRESSION VECTORS CONTAINING SAID SYNTHETIC GENES | June 2022 | December 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17834026 | CELL CULTURE MEDIA CONTAINING COMBINATIONS OF PROTEINS | June 2022 | September 2022 | Allow | 4 | 0 | 1 | Yes | No |
| 17782505 | REGULATABLE EXPRESSION SYSTEMS | June 2022 | November 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17829316 | NUCLEIC ACID-GUIDED NUCLEASES | May 2022 | July 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17778656 | INSULINOTROPIC AND GLUCAGONOTROPIC EFFECTS OF BETA-LACTOGLOBULIN | May 2022 | October 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17778783 | ADENO-ASSOCIATED VIRAL VECTOR VARIANTS | May 2022 | February 2026 | Allow | 45 | 2 | 0 | Yes | No |
| 17734809 | NANOPARTICLE BIOHYBRID COMPLEXES | May 2022 | July 2025 | Abandon | 38 | 3 | 0 | No | No |
| 17731201 | VGLL4 WITH UCP-1 CIS-REGULATORY ELEMENT AND METHOD OF USE THEREOF | April 2022 | April 2025 | Allow | 35 | 0 | 0 | No | No |
| 17728978 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR RECOVERING WATER-IMMISCIBLE COMPOUNDS FROM MICROBIAL BIOMASS | April 2022 | February 2024 | Allow | 21 | 1 | 0 | No | No |
| 17727588 | CHLOROPHYTE ALGAE HAVING IMPROVED PRODUCTIVITY | April 2022 | January 2026 | Allow | 44 | 1 | 1 | Yes | No |
| 17719742 | Compositions and Methods for Cell-Based Assays | April 2022 | June 2025 | Allow | 38 | 2 | 0 | No | No |
| 17720186 | COMPOSITIONS AND METHODS FOR TREATING HEMOGLOBINOPATHIES | April 2022 | April 2023 | Allow | 12 | 0 | 0 | Yes | No |
| 17717313 | METHODS AND COMPOSITIONS RELATED TO RECOMBINANT NEIL2 | April 2022 | August 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17717601 | Glycosyl Hydrolases | April 2022 | September 2025 | Allow | 41 | 1 | 1 | No | No |
| 17715602 | ENRICHMENT OF AMINO ACIDS FROM BIOMASS RESIDUUM | April 2022 | December 2024 | Allow | 32 | 4 | 0 | Yes | No |
| 17705772 | TRANSGLUTAMINASE VARIANTS | March 2022 | December 2023 | Abandon | 20 | 0 | 1 | No | No |
| 17706466 | CLASS II, TYPE V CRISPR SYSTEMS | March 2022 | February 2023 | Allow | 11 | 1 | 1 | Yes | No |
| 17762974 | RENEWABLE CHEMICAL PRODUCTION ENGAGING METATHESIS AND MICROBIAL OXIDATION | March 2022 | July 2024 | Allow | 28 | 4 | 0 | Yes | No |
| 17695856 | ESCHERICHIA COLI FOR PRODUCING 5-AMINO- LEVULINIC ACID AND METHOD OF PRODUCING 5-AMINOLEVULINIC ACID | March 2022 | August 2024 | Abandon | 29 | 2 | 1 | No | No |
| 17760711 | DACH1 BUILDS ARTERY NETWORKS THAT PROTECT AGAINST CARDIAC INJURY IN ADULTS | March 2022 | October 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17692069 | NUCLEIC ACID-GUIDED NUCLEASES | March 2022 | July 2024 | Allow | 28 | 2 | 0 | Yes | No |
| 17641754 | AAV-ZYME AND USE FOR INFUSION REPLACEMENT THERAPY | March 2022 | January 2026 | Abandon | 46 | 1 | 1 | No | No |
| 17684277 | COMPOSITIONS AND METHODS FOR EXTRACTION OF MESENCHYMAL STEM CELLS | March 2022 | January 2023 | Abandon | 10 | 1 | 0 | No | No |
| 17680289 | METHODS FOR INCREASING OBSERVED EDITING IN BACTERIA | February 2022 | September 2023 | Allow | 19 | 1 | 0 | Yes | No |
| 17680337 | DETERGENT COMPOSITION | February 2022 | February 2024 | Allow | 24 | 2 | 0 | Yes | No |
| 17680479 | COMPOSITIONS AND METHODS FOR PRODUCING ADENO-ASSOCIATED VIRAL VECTORS | February 2022 | September 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17674220 | DESTABILISING DOMAINS FOR CONDITIONALLY STABILISING A PROTEIN | February 2022 | March 2024 | Allow | 25 | 2 | 0 | Yes | No |
| 17588256 | NUCLEIC ACID-GUIDED NUCLEASES | January 2022 | May 2022 | Allow | 4 | 1 | 0 | Yes | No |
| 17630488 | MUTATED PGLB OLIGOSACCHARYLTRANSFERASE ENZYMES | January 2022 | November 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17627052 | TREATMENT OF NEURONAL DISEASES | January 2022 | October 2025 | Abandon | 45 | 1 | 1 | No | No |
| 17572055 | SAFE AND EFFECTIVE BETA-LACTAMASE DOSING FOR MICROBIOME PROTECTION | January 2022 | August 2023 | Allow | 19 | 2 | 0 | No | No |
| 17554736 | NUCLEIC ACID-GUIDED NUCLEASES | December 2021 | March 2022 | Allow | 2 | 0 | 0 | Yes | No |
| 17551890 | NOVEL ADENYLOSUCCINATE SYNTHETASE AND METHOD FOR PRODUCING PURINE NUCLEOTIDES USING THE SAME | December 2021 | February 2023 | Allow | 14 | 0 | 0 | No | No |
| 17546810 | Modulating Human Cas9-Specific Host Immune Response | December 2021 | April 2024 | Allow | 28 | 1 | 1 | Yes | No |
| 17536067 | METHODS FOR INCREASING OBSERVED EDITING IN BACTERIA | November 2021 | February 2022 | Allow | 3 | 0 | 0 | Yes | No |
| 17533004 | METHODS FOR INCREASING MANNOSE CONTENT OF RECOMBINANT PROTEINS | November 2021 | April 2022 | Allow | 5 | 1 | 0 | No | No |
| 17528619 | PICHIA PASTORIS STRAINS FOR PRODUCING PREDOMINANTLY HOMOGENEOUS GLYCAN STRUCTURE | November 2021 | August 2023 | Allow | 21 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HOLLAND, PAUL J.
With a 31.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HOLLAND, PAUL J works in Art Unit 1656 and has examined 771 patent applications in our dataset. With an allowance rate of 58.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner HOLLAND, PAUL J's allowance rate of 58.2% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HOLLAND, PAUL J receive 2.29 office actions before reaching final disposition. This places the examiner in the 64% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HOLLAND, PAUL J is 33 months. This places the examiner in the 46% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +71.4% benefit to allowance rate for applications examined by HOLLAND, PAUL J. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.3% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 27.9% of cases where such amendments are filed. This entry rate is in the 39% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 80.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 62% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 66.0% of appeals filed. This is in the 47% percentile among all examiners. Of these withdrawals, 71.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 67.5% are granted (fully or in part). This grant rate is in the 75% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.4% of allowed cases (in the 58% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 54% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.